Atlas Trials

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Clinical trial NCT05157542 · UNKNOWN

Trial details

NCT number
NCT05157542
Sponsor
Juan LI, MD
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Stage III Non-small Cell Lung Cancer
Start date
2021-06-10
Primary completion
2023-06-10
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.